compounded semaglutide lawsuit Hims & Hers Health (HIMS) Securities Class Action Update Compound versions of GLP-1 drugs

However, beginning Jan

l , AUC of k

3163 ( IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation) is active and exclusively for claims involving partial blindness/vision loss caused by GLP-1 use

While both formulations contain identical active medication, their pharmacokinetic profiles differ significantly due to their routes of administration

In 2025, nearly three-quarters (72%) face an out-of-pocket maximum of more than $3,000 for single coverage, including one in five (21%) who face an out-of-pocket maximum of more than $6,000

For many Canadians, this changes the calculation significantly